BEIJING - China's powerful National Development and Reform Commission, which has a virtually unrestricted purview over setting prices for medicines that are included on the country's Essential Drug List, is in the final stages of determining caps for every item on the newly revised list
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lynkuet will compete with Astellas's Veozah/Veoza
The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.
Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.
